MedTrace Logo

Safety Study of Gleevec® in Children With Pulmonary Hypertension

NCT00583115 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2015-10-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out if the drug, Gleevec, is safe and effective in treating children with Pulmonary Hypertension.

Conditions

  • Pulmonary Hypertension

Interventions

DRUG

Gleevec

260 mg/M2/day, given once daily by mouth

Sponsors & Collaborators

  • Indiana University

    lead OTHER

Principal Investigators

  • R. Mark Payne, MD · Indiana University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
8 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2013-08-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00583115 on ClinicalTrials.gov